BiotechTube

DFA-02 Antibiotic Gel + DFA-02 Placebo Gel

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Surgical Site Infections

Conditions

Surgical Site Infections

Trial Timeline

Oct 1, 2013 → Feb 1, 2015

NCT ID
NCT01888367

About DFA-02 Antibiotic Gel + DFA-02 Placebo Gel

DFA-02 Antibiotic Gel + DFA-02 Placebo Gel is a phase 2 stage product being developed by Dr. Reddy's Laboratories for Surgical Site Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01888367. Target conditions include Surgical Site Infections.

What happened to similar drugs?

7 of 20 similar drugs in Surgical Site Infections were approved

Approved (7) Terminated (5) Active (10)
✅Epoetin alfa + Standard of CareJohnson & JohnsonApproved
✅ErtapenemMerckApproved
✅Sugammadex + RocuroniumMerckApproved
✅Deep neuromuscular blockMerckApproved
✅RocuroniumMerckApproved
✅parecoxib/valdecoxibPfizerApproved
✅Tranexamic acid + Standard of CarePfizerApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01888367Phase 2Completed

Competing Products

20 competing products in Surgical Site Infections

See all competitors
ProductCompanyStageHype Score
DFA-02 + PlaceboDr. Reddy's LaboratoriesPhase 1/2
29
CelecoxibAstellas PharmaPre-clinical
26
Nivolumab + EverolimusOno PharmaceuticalPhase 3
40
Epoetin alfa + Standard of CareJohnson & JohnsonApproved
35
HR021618 + HR021618 + PlaceboJiangsu Hengrui MedicinePhase 2
31
SHR0410 Injection + Placebo for SHR0410 InjectionJiangsu Hengrui MedicinePhase 2
27
ErtapenemMerckApproved
43
Sugammadex + RocuroniumMerckApproved
43
Deep neuromuscular blockMerckApproved
43
RocuroniumMerckApproved
43
ErtapenemMerckPhase 2/3
38
Sugammadex + Neostigmine + GlycopyrrolateMerckPhase 3
40
Ecallantide + PlaceboMerckPhase 2
27
Amicidin-β topical solution - 15 mL + Amicidin-β topical solution - 50 mL + Standard of Care (SOC)Novo NordiskPhase 1
36
Insulin infusion with a goalNovo NordiskPhase 3
40
parecoxib/valdecoxibPfizerApproved
35
Tranexamic acid + Standard of CarePfizerApproved
43
Ibuprofen 250 mg / Acetaminophen 500 mg + Ibuprofen 250 mg + Acetaminophen 650 mg + PlaceboPfizerPhase 3
40
valdecoxib + valdecoxib/placebo + placeboPfizerPhase 3
40
PF-04531083 + PF-04531083 + IbuprofenPfizerPhase 2
27